RxDoctor Payments Data

Sabeen Lulu, MD

Neurology · Carmichael, CANPI 1104081298

Payments from drug & device makers

$245,537in general payments, 2019–2025

Across 134 payments — averaging $1832.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$102K
  • Biogen$86K
  • Sanofi$17K
  • Genentech, Inc.$13K
  • Roche Products Limited$12K
  • Genentech USA, Inc.$7K
  • plus $7K from 7 others

What the payments were for

  • Consulting fees$20,36517%
  • Speaking & faculty fees$93,53879%
  • Travel & lodging$1,1891%
  • Food & beverage$3,2263%
  • Education$560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$245,537 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$129,907
Medicare patients
304
Services billed
6,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab85$740,979
CopaxoneGlatiramer Acetate81$480,465
AubagioTeriflunomide14$180,934
Plegridy PenPeginterferon Beta-1a11$163,265
Avonex (4 Pack)Interferon Beta-1a15$148,064
TecfideraDimethyl Fumarate15$132,311
VumerityDiroximel Fumarate12$105,624
GlatopaGlatiramer Acetate20$66,557
Nurtec OdtRimegepant Sulfate34$62,291
Glatiramer Acetate28$59,863
Teriflunomide64$37,322
Dalfampridine ErDalfampridine136$27,209
Dimethyl Fumarate49$24,409
Emgality PenGalcanezumab-Gnlm29$20,596
UbrelvyUbrogepant14$15,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack), Tecfidera, Vumerity$86,275$385,99842 claims
SanofiAubagio$17,244$180,93414 claims
AbbVieUbrelvy$57$15,65014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in Carmichael

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →